Fluticasone propionate given by inhalation offers preventative treatment for asthma. At recommended doses it has a potent glucocorticoid anti-inflammatory action within the lungs, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically.
Prophylactic management of asthma.
Symptomatic treatment of chronic obstructive pulmonary disease (COPD).
Clinical Studies : Pharmacokinetic studies and phase III study.
Our product has been developed as capsules containing dry powder for inhalation at a fluticasone dosage of 125 µg and 250 µg in HPMC capsules to be used in the Axahaler® DPI device. Laboratoires SMB’s product has enhanced bioavailability where the same efficacy has been proven clinically with half the dose of the reference product.
Publications : Izabela Kupryś-Lipińska, Damian Tworek, Francis Vanderbist, Małgorzata Bocheńska-Marciniak, Piotr Kuna. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma. Pneumonol Alergol Pol 2013 ;81(6):527-36.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy Policy